ProCE Banner Activity

Generic vs Brand Name Imatinib for Untreated Chronic-Phase Chronic Myeloid Leukemia: Findings From an Observational Cohort Study

Slideset Download
Conference Coverage
Nonrandomized, observational study suggests reduced event-free survival in patients receiving generic vs branded imatinib.

Released: December 05, 2018

Expiration: December 04, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology